A5038265124- Inflammatory Bowel Disease
- Microscopic Colitis
- Helicobacter pylori-related gastroenterology studies
- Eosinophilic Esophagitis
- Autoimmune and Inflammatory Disorders
- Immunodeficiency and Autoimmune Disorders
- Celiac Disease Research and Management
- Diagnosis and treatment of tuberculosis
- Pregnancy and Medication Impact
- Gastric Cancer Management and Outcomes
- Liver Diseases and Immunity
- Diverticular Disease and Complications
- Acute Lymphoblastic Leukemia research
- Biosimilars and Bioanalytical Methods
- Systemic Lupus Erythematosus Research
- Gastrointestinal motility and disorders
- Reproductive System and Pregnancy
- Tuberculosis Research and Epidemiology
- Gastrointestinal disorders and treatments
- Mycobacterium research and diagnosis
- Stoma care and complications
- Pharmaceutical studies and practices
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Appendicitis Diagnosis and Management
Hospital Universitari Germans Trias i Pujol
2016-2025
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2016-2025
Instituto de Salud Carlos III
2018-2025
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
2008-2025
Medical Research Network
2025
Centro de Investigación Biomédica en Red
2015-2024
Universitat Autònoma de Barcelona
2009-2024
Central University Hospital of Asturias
2024
Hospital Universitario Puerta de Hierro Majadahonda
2024
Hospital de Sant Pau
2024
The safety of thiopurines and anti-tumor necrosis factor-α (TNF-α) drugs during pregnancy remains controversial, as the experience with these in this situation is limited. Our aim to assess anti-TNF-α for treatment inflammatory bowel disease (IBD) pregnancy.Retrospective, multicenter study IBD patients. Pregnancies were classified according therapeutic regimens or 3 months before conception: non-exposed group, pregnancies exposed alone (group A), B). An unfavorable Global Pregnancy Outcome...
The efficacy of infliximab therapy in patients with Crohn's disease (CD) is unknown beyond 12 months. For who lose their initial response, consideration can be given to dose "escalation" regain therapeutic benefit.Our primary goal was evaluate the long-term durability maintenance treatment. secondary goals were identify potential predictors loss efficacy, response escalation, and safety treatment without escalation dose.CD treated an induction regimen evaluated. Maintenance estimated using...
Aliment Pharmacol Ther 2012; 35: 275–283 Summary Background Ciclosporin has proven to be effective in patients with corticosteroid‐refractory ulcerative colitis (UC). When therapy this drug fails, infliximab can considered avoid colectomy. The efficacy and safety of sequential approach remain unknown. Aim To assess the profile treatment after failure ciclosporin a flare UC. Methods Retrospective review medical records UC who did not respond received salvage within month discontinuing...
The aims of this study were to assess the risk relapse after discontinuation anti-tumor necrosis factor (anti-TNF) drugs in patients with inflammatory bowel disease (IBD), identify factors associated relapse, and evaluate overcome retreatment same anti-TNF those who relapsed.This was a retrospective, observational, multicenter study. IBD had been treated anti-TNFs whom these discontinued clinical remission achieved included.A total 1,055 included. incidence rate 19% 17% per patient-year...
BackgroundFecal calprotectin (FC) is considered the best noninvasive way to assess disease activity in ulcerative colitis (UC). However, it not known which more suitable moment for stool sampling patients with increased frequency. The aims of this study were intraindividual variation FC within day and evaluate if first bowel movement morning sample measurement acute flares UC.
Effectiveness of vedolizumab in real world clinical practice is unknown.To evaluate the short and long-term effectiveness patients with inflammatory bowel disease (IBD).Patients who received at least 1 induction dose were included. was defined based on Harvey-Bradshaw index (HBI) Crohn's (CD) Partial Mayo Score (PMS) ulcerative colitis (UC). Short-term response assessed week 14. Variables associated short-term remission identified by logistic regression analysis. The Kaplan-Meier method used...
The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed clinical practice. We aimed to evaluate the durability, effectiveness, and safety UC real life.Patients included prospectively maintained ENEIDA registry, who received at least one intravenous dose due active [Partial Mayo Score [PMS]>2], were included. Clinical activity effectiveness defined based on PMS. Short-term response was assessed Week 16.A total 95...
Postoperative recurrence (PR) occurs early after intestinal resection in >75% of Crohn's disease (CD) patients. No well-established strategy for long-term PR prevention is available. The aim was to prospectively evaluate the endoscopic and clinical outcomes postoperative CD on maintenance treatment with azathioprine (AZA), especially patients who developed lesions confined ileocolic anastomosis.Long-term AZA therapy (2-2.5 mg/kg/day) initiated immediately surgery 56 consecutive underwent a...
Despite medical therapy, 30% of patients with ulcerative colitis (UC) need to undergo surgery. Around 50% proctocolectomy ileal pouch-anal anastomosis (IPAA) develop complications the pouch. Clinical evidence for use infliximab (IFX) in refractory pouchitis is limited. The aim this study was report efficacy IFX these patients.A retrospective, multicenter designed. Patients older than 18 years chronic treated (5 mg/kg) were included. Short-term evaluated at week 8 and mid-term weeks 26 52....
Aim. The aim was to assess the impact of inflammatory bowel disease (IBD) and its treatment on fertility, pregnancy outcomes, breastfeeding. IBD is a chronic condition that usually diagnosed in young adulthood. Patients are often concerned about fertility outcomes. Methods. A structured questionnaire posted 850 adults with followed-up single center. Results. total 503 patients (59%) median age 40 years equally distributed for gender type returned questionnaire. Overall, 71% had 659 children,...
In refractory pouchitis, infliximab (IFX) has been used as rescue therapy; however, there is no clinical evidence for the use of adalimumab (ADA). The aim this study was to report efficacy ADA in patients with pouchitis previously treated IFX.A retrospective, open-label, case series designed. Patients chronic were included. All IFX. short-term and mid-term evaluated.Eight After 8 weeks, 13% achieved remission 62% showed a response. At week 26, 38% 52, 50% avoided permanent ileostomy but only...
Psoriasis induced by anti-tumor necrosis factor-α (TNF) therapy has been described as a paradoxical side effect.To determine the incidence, clinical characteristics, and management of psoriasis anti-TNF in large nationwide cohort inflammatory bowel disease patients.Patients with were identified from Spanish prospectively maintained Estudio Nacional en Enfermedad Inflamatoria Intestinal sobre Determinantes genéticos y Ambientales registry Grupo Español de Trabajo Croh Colitis Ulcerosa....
Summary Background Onset during old age has been reported in upto 10% of total cases inflammatory bowel disease ( IBD ). Aim To evaluate phenotypic characteristics and the use therapeutic resources patients with elderly onset . Methods Case‐control study including all those diagnosed over 60 years since 2000 who were followed‐up for >12 months, identified from databases. Elderly compared aged 18 to 40 at diagnosis, matched by year gender type (adult‐onset). Results One thousand three...
Abstract Despite the introduction of biological therapies, an ileocolonic resection is often required in patients with Crohn’s disease [CD]. Unfortunately, surgery not curative, as many will develop postoperative recurrence [POR], eventually leading to further bowel damage and a decreased quality life. The 8th Scientific Workshop ECCO reviewed available scientific data on both prevention treatment POR CD undergoing resection, dealing conventional well non-medical interventions, including...
Abstract Background and Aims No consensus exists on optimal strategy to prevent postoperative recurrence [POR] after ileocaecal resection [ICR] for Crohn’s disease [CD]. We compared early medical prophylaxis versus expectant management with treatment driven by findings at elective endoscopy 6–12 months ICR. Methods A retrospective, multicentric, observational study was performed. CD patients undergoing first ICR were assigned Cohort 1 if a biologic or immunomodulator [re]started...
Management of abdominal abscesses (AA) in Crohn's disease (CD) always includes antibiotics, and some type drainage is added according to the response other considerations. Our aim was assess efficacy different therapeutic approaches spontaneous AA CD.All cases CD were identified from databases five university hospitals. Postoperative excluded. Therapeutic success defined as abscess resolution nonreappearance within 1 year follow-up.We 128 2236 patients (cumulative incidence 5.7%). Initial...
Objectives: To determine the efficacy and safety of cyclosporine (CyA) in a large national registry-based population patients with steroid-refractory (SR) acute severe ulcerative colitis (ASUC) to establish predictors adverse events. Methods: Multicenter study SR-ASUC treated CyA, based on data from ENEIDA registry. infliximab (IFX) or sequential rescue therapy (CyA-IFX IFX-CyA) were used as comparators. Results: Of 740 patients, 377 received 131 IFX 63 therapy. The cumulative colectomy rate...
Endoscopic recurrence occurs in up to 80% of patients with Crohn’s disease 1 year after intestinal resection. Imidazole antibiotics, thiopurines, and particularly their combination have proven efficacy preventing endoscopic recurrence. The aim the study was compare addition metronidazole (for 3 months surgical treatment) azathioprine for prevention postsurgical A pilot made 50 undergoing resection ileocolic anastomosis treated 2 2.5 mg/kg per day year. were randomized receive additional 15...
Glucocorticosteroids are the first line therapy for moderate-severe flare-ups of ulcerative colitis. Despite that, up to 60% patients do not respond adequately steroid treatment. Previously, we reported that low IL-10 mRNA levels in intestine associated with a poor response glucocorticoids active Crohn's disease. Here, test whether can favour by improving TNFα-induced intestinal barrier damage (assessed transepithelial electrical resistance) Caco-2 monolayers, and their possible implications...
Summary Background Thiopurines are the most widely used immunosuppressants in IBD although drug‐related adverse events (AE) occur 20%‐30% of cases. Aim To evaluate safety thiopurines elderly patients Methods Cohort study including all adult ENEIDA registry who received thiopurines. Patients were grouped terms age at beginning thiopurine treatment, specifically those started over 60 years or between 18 and 50 age. Thiopurine‐related AEs registered database compared. Results Out 48 752...